Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P; EU/US/CTAD Task Force Members. Vellas B, et al. Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007. Alzheimers Dement. 2013. PMID: 23809364
Methodological issues in primary prevention trials for neurodegenerative dementia.
Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, Fillit H, Frisoni GB, Froelich L, Gauthier S, Jones R, Jönsson L, Khachaturian Z, Morris JC, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Andrieu S, et al. Among authors: wilcock g. J Alzheimers Dis. 2009;16(2):235-70. doi: 10.3233/JAD-2009-0971. J Alzheimers Dis. 2009. PMID: 19221415 Review.
Biomarkers for Alzheimer's disease therapeutic trials.
Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group. Hampel H, et al. Among authors: wilcock g. Prog Neurobiol. 2011 Dec;95(4):579-93. doi: 10.1016/j.pneurobio.2010.11.005. Epub 2010 Dec 2. Prog Neurobiol. 2011. PMID: 21130138 Review.
Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.
Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, Mintun M, Morris J, Petersen R, Thomas RG, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio C, Aisen P; Task Force Participants. Vellas B, et al. J Nutr Health Aging. 2012 Apr;16(4):339-45. doi: 10.1007/s12603-012-0044-x. J Nutr Health Aging. 2012. PMID: 22499454 Free article.
What we have learned from the Myriad trials.
Hendrix SB, Wilcock GK. Hendrix SB, et al. Among authors: wilcock gk. J Nutr Health Aging. 2009 Apr;13(4):362-4. doi: 10.1007/s12603-009-0044-7. J Nutr Health Aging. 2009. PMID: 19300881 Free article. No abstract available.
Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study.
Damian M, Hausner L, Jekel K, Richter M, Froelich L, Almkvist O, Boada M, Bullock R, De Deyn PP, Frisoni GB, Hampel H, Jones RW, Kehoe P, Lenoir H, Minthon L, Olde Rikkert MG, Rodriguez G, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B, Verhey FR, Winblad B, Wahlund LO, Wilcock G, Visser PJ. Damian M, et al. Among authors: wilcock g. Dement Geriatr Cogn Disord. 2013;36(1-2):1-19. doi: 10.1159/000348354. Epub 2013 May 3. Dement Geriatr Cogn Disord. 2013. PMID: 23651945
The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.
Bocchetta M, Galluzzi S, Kehoe PG, Aguera E, Bernabei R, Bullock R, Ceccaldi M, Dartigues JF, de Mendonça A, Didic M, Eriksdotter M, Félician O, Frölich L, Gertz HJ, Hallikainen M, Hasselbalch SG, Hausner L, Heuser I, Jessen F, Jones RW, Kurz A, Lawlor B, Lleo A, Martinez-Lage P, Mecocci P, Mehrabian S, Monsch A, Nobili F, Nordberg A, Rikkert MO, Orgogozo JM, Pasquier F, Peters O, Salmon E, Sánchez-Castellano C, Santana I, Sarazin M, Traykov L, Tsolaki M, Visser PJ, Wallin ÅK, Wilcock G, Wilkinson D, Wolf H, Yener G, Zekry D, Frisoni GB. Bocchetta M, et al. Among authors: wilcock g. Alzheimers Dement. 2015 Feb;11(2):195-206.e1. doi: 10.1016/j.jalz.2014.06.006. Epub 2014 Aug 20. Alzheimers Dement. 2015. PMID: 25150733 Free article.
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Burns A, O'Brien J; BAP Dementia Consensus group; Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology. Burns A, et al. Among authors: wilcock g. J Psychopharmacol. 2006 Nov;20(6):732-55. doi: 10.1177/0269881106068299. J Psychopharmacol. 2006. PMID: 17060346 Review.
313 results